Anaphylaxis after administration of ibritumomab tiuxetan for follicular non-hodgkin lymphoma

Clin Nucl Med. 2008 Feb;33(2):94-6. doi: 10.1097/RLU.0b013e31815ef825.


We report an anaphylactic reaction in a 45-year-old gentleman with an 8-year history of extensively treated, relapsing follicular lymphoma who was receiving a second treatment with ibritumomab tiuxetan. Within seconds of receiving Y-90 ibritumomab, he developed chest tightness, shallow respirations, hypotension, and incontinence. After successful resuscitation, a human antimouse antibody (HAMA) level was found to be elevated, 618 ng/mL (reference 0-188 ng/mL).

Publication types

  • Case Reports

MeSH terms

  • Anaphylaxis / chemically induced*
  • Antibodies, Monoclonal / adverse effects*
  • Enzyme-Linked Immunosorbent Assay
  • Humans
  • Lymphoma, Follicular / radiotherapy*
  • Male
  • Middle Aged
  • Radioimmunotherapy / methods
  • Yttrium Radioisotopes / adverse effects


  • Antibodies, Monoclonal
  • Yttrium Radioisotopes
  • ibritumomab tiuxetan